GSK PLC SP. ADR/2 NEW (GS70) - Net Assets
Based on the latest financial reports, GSK PLC SP. ADR/2 NEW (GS70) has net assets worth €17.42 Billion EUR (≈ $20.37 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€62.87 Billion ≈ $73.50 Billion USD) and total liabilities (€45.45 Billion ≈ $53.13 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore GS70 cash generation efficiency to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €17.42 Billion |
| % of Total Assets | 27.71% |
| Annual Growth Rate | -7.01% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 31.53 |
GSK PLC SP. ADR/2 NEW - Net Assets Trend (2021–2025)
This chart illustrates how GSK PLC SP. ADR/2 NEW's net assets have evolved over time, based on quarterly financial data. Also explore GS70 current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for GSK PLC SP. ADR/2 NEW (2021–2025)
The table below shows the annual net assets of GSK PLC SP. ADR/2 NEW from 2021 to 2025. For live valuation and market cap data, see GSK PLC SP. ADR/2 NEW market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €15.96 Billion ≈ $18.65 Billion |
+21.93% |
| 2024-12-31 | €13.09 Billion ≈ $15.30 Billion |
+2.27% |
| 2023-12-31 | €12.79 Billion ≈ $14.96 Billion |
+26.73% |
| 2022-12-31 | €10.10 Billion ≈ $11.80 Billion |
-52.69% |
| 2021-12-31 | €21.34 Billion ≈ $24.95 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to GSK PLC SP. ADR/2 NEW's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 28.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €10.21 Billion | 62.34% |
| Other Components | €6.17 Billion | 37.66% |
| Total Equity | €16.38 Billion | 100.00% |
GSK PLC SP. ADR/2 NEW Competitors by Market Cap
The table below lists competitors of GSK PLC SP. ADR/2 NEW ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
UBS Group AG
SW:UBSG
|
$101.41 Billion |
|
Sanofi
MX:SNYN
|
$101.48 Billion |
|
China Life Insurance Co Ltd A
SHG:601628
|
$101.96 Billion |
|
BNP Paribas SA
PA:BNP
|
$103.16 Billion |
|
Trane Technologies plc
NYSE:TT
|
$101.30 Billion |
|
CME Group Inc
NASDAQ:CME
|
$101.13 Billion |
|
Eoptolink Technology Inc Ltd
SHE:300502
|
$101.09 Billion |
|
Air Liquide SA
PA:AI
|
$101.06 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GSK PLC SP. ADR/2 NEW's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 13,671,000,000 to 16,377,000,000, a change of 2,706,000,000 (19.8%).
- Net income of 5,716,000,000 contributed positively to equity growth.
- Dividend payments of 2,564,000,000 reduced retained earnings.
- Share repurchases of 1,377,000,000 reduced equity.
- New share issuances of 15,000,000 increased equity.
- Other factors increased equity by 916,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €5.72 Billion | +34.9% |
| Dividends Paid | €2.56 Billion | -15.66% |
| Share Repurchases | €1.38 Billion | -8.41% |
| Share Issuances | €15.00 Million | +0.09% |
| Other Changes | €916.00 Million | +5.59% |
| Total Change | €- | 19.79% |
Book Value vs Market Value Analysis
This analysis compares GSK PLC SP. ADR/2 NEW's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.56x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 12.62x to 11.56x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €3.74 | €47.20 | x |
| 2022-12-31 | €2.59 | €47.20 | x |
| 2023-12-31 | €3.29 | €47.20 | x |
| 2024-12-31 | €3.35 | €47.20 | x |
| 2025-12-31 | €4.08 | €47.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GSK PLC SP. ADR/2 NEW utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 34.90%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.50%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 3.73x
- Recent ROE (34.90%) is below the historical average (52.18%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 29.13% | 17.76% | 0.31x | 5.25x | €2.88 Billion |
| 2022 | 141.12% | 51.00% | 0.49x | 5.68x | €13.90 Billion |
| 2023 | 36.92% | 16.25% | 0.51x | 4.42x | €3.59 Billion |
| 2024 | 18.84% | 8.21% | 0.53x | 4.35x | €1.21 Billion |
| 2025 | 34.90% | 17.50% | 0.53x | 3.73x | €4.08 Billion |
Industry Comparison
This section compares GSK PLC SP. ADR/2 NEW's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $196,397,425,667
- Average return on equity (ROE) among peers: 11.74%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GSK PLC SP. ADR/2 NEW (GS70) | €17.42 Billion | 29.13% | 2.61x | $101.34 Billion |
| Bayer AG NA (BAYN) | $47.52 Billion | 8.61% | 1.66x | $36.43 Billion |
| Cosmo Pharmaceuticals N.V (C43) | $463.79 Million | 3.71% | 0.64x | $1.65 Billion |
| CSPC Pharmaceutical Group Limited (CVG) | $19.52 Billion | 19.03% | 0.35x | $10.04 Billion |
| CSPC PHARMACEUT.GR. ADR4 (CVGU) | $31.64 Billion | 19.25% | 0.32x | $11.04 Billion |
| GRIFOLS ADR 1/2/EO-50 (G0F) | $8.61 Billion | 1.82% | 1.49x | $4.21 Billion |
| Grifols S.A (G0FB) | $3.73 Billion | 14.63% | 1.72x | $4.42 Billion |
| ORION CORP.B UNSP.ADR 1/2 (OFK0) | $1.00 Billion | 32.83% | 0.62x | $8.31 Billion |
| Sanofi (SNW2) | $59.11 Billion | 4.75% | 0.91x | $105.72 Billion |
| ASTELLAS PHARMA UNSP.ADR (YPHA) | $1.60 Trillion | 1.07% | 1.24x | $19.55 Billion |
About GSK PLC SP. ADR/2 NEW
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more